Aug 24 (Reuters) - ImmuCell Corp ICCC.O :
* IMMUCELL REQUIRED TO PREPARE SECOND SUBMISSION OF FINAL
MAJOR
TECHNICAL SECTION FOR RE-TAIN®
* IMMUCELL CORP - FDA HAS ISSUED TECHNICAL SECTION
INCOMPLETE
LETTER COVERING CHEMISTRY, MANUFACTURING AND CONTROLS TECHNICAL
SECTION FOR RE-TAIN
* IMMUCELL CORP - CAN RESPOND WITH A RE-SUBMISSION OF CMC
TECHNICAL SECTION DURING Q4 OF 2021 WITHOUT INCURRING
SIGNIFICANT COSTS OR DELAYS
* IMMUCELL CORP - POTENTIAL MARKET LAUNCH OF RE-TAIN
EXPECTED
DURING Q3 OF 2022
Source text for Eikon: ID:nGNX9CpZB9
Further company coverage: ICCC.O
((reuters.briefs@thomsonreuters.com;))